Home » Stocks » ZLAB

Zai Lab Limited (ZLAB)

Stock Price: $157.30 USD -3.79 (-2.35%)
Updated Jun 18, 2021 4:00 PM EDT - Market closed
Market Cap 15.14B
Revenue (ttm) 60.84M
Net Income (ttm) n/a
Shares Out 94.68M
EPS (ttm) -5.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 18
Last Price $157.30
Previous Close $161.09
Change ($) -3.79
Change (%) -2.35%
Day's Open 159.37
Day's Range 154.95 - 160.66
Day's Volume 1,299,697
52-Week Range 71.79 - 193.54

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SHANGHAI, SAN FRANCISCO and ROCKVILLE, MD, June 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and MacroGenics (NASDAQ...

4 days ago - GlobeNewsWire

Benjamin Graham, the father of value investing, suggested screening the market for stocks that have a current ratio of more than 2 plus more working capital than long-term debt.

Other stocks mentioned: CREE, TECH
2 weeks ago - GuruFocus

SAN DIEGO and SHANGHAI and SAN FRANCISCO, June 1, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688...

Other stocks mentioned: MRTX
2 weeks ago - PRNewsWire

SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced dosing of the first pati...

3 weeks ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that manage...

3 weeks ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced treatment of the first ...

3 weeks ago - GlobeNewsWire

Company to Host Conference Call and Webcast Today at 8:00 a.m. EDT Company to Host Conference Call and Webcast Today at 8:00 a.m. EDT

1 month ago - GlobeNewsWire

Company to Host Conference Call and Webcast on May 10, 2021 at 8:00 a.m. ET Company to Host Conference Call and Webcast on May 10, 2021 at 8:00 a.m. ET

1 month ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, April 23, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB, HKEX: 9688), an innovative commercial stage biopharmaceutical company, today ann...

1 month ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, April 20, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB, HKEX: 9688), an innovative commercial stage biopharmaceutical company, today ann...

2 months ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, April 19, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB, HKEX: 9688), an innovative commercial stage biopharmaceutical company, today ann...

2 months ago - GlobeNewsWire

Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial

2 months ago - GlobeNewsWire

China NMPA approval follows 2020 U.S. FDA approval for the treatment of patients with fourth-line GIST

2 months ago - GlobeNewsWire

If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covi...

Other stocks mentioned: DNLI, FATE, MRNA, MRTX, NVAX, SGEN
3 months ago - InvestorPlace

Company to Host Conference Call and Webcast on March 1, 2021 at 8:00 a.m. ET Company to Host Conference Call and Webcast on March 1, 2021 at 8:00 a.m. ET

4 months ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that senior management...

4 months ago - GlobeNewsWire

Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point's MET/SRC/CSF1R Inhibitor, in Greater China

5 months ago - GlobeNewsWire

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up...

Other stocks mentioned: ARGX, EYPT, GILD, GRCL, INO, LLY, PRTK
5 months ago - Seeking Alpha

Regulated Information/Inside Information

5 months ago - GlobeNewsWire

These companies made millions by developing equipment for life-saving care, and enriched shareholders too.

Other stocks mentioned: AHCO, IRTC, RVP, SMTI
5 months ago - The Motley Fool

SHANGHAI and SAN FRANCISCO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that Dr. S...

5 months ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA® has been ...

5 months ago - GlobeNewsWire

- Zai Lab to lead development and commercialization of CLN-081 in Greater China

5 months ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited's (NASDAQ: ZLAB; HKEX: 9688) partner MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and...

6 months ago - GlobeNewsWire

It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

Other stocks mentioned: BNTX, CRSP, DNLI, MRTX, NVAX, SGEN
6 months ago - InvestorPlace

SHANGHAI and SAN FRANCISCO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the appoin...

6 months ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited's (NASDAQ: ZLAB; HKEX: 9688) partner Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company fo...

7 months ago - GlobeNewsWire

The Vanguard Health Care Fund (Trades, Portfolio) released its third-quarter portfolio earlier this week.

Other stocks mentioned: LH, QDEL
7 months ago - GuruFocus

CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint recep...

Other stocks mentioned: CASI, INCY, OCUL
7 months ago - Seeking Alpha

SHANGHAI and SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced dosing of the first pa...

7 months ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced that manag...

7 months ago - GlobeNewsWire

10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million.

Other stocks mentioned: CRVS, INCY, TXG
8 months ago - Seeking Alpha

SHANGHAI and SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced full exercise of the over-al...

8 months ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced dosing of the first patient ...

8 months ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced dosing of the first patient ...

8 months ago - GlobeNewsWire

Zai Lab raised $761 million in a Hong Kong IPO and rose 8.5% in its first trading session to a market cap of $6.8 billion.

8 months ago - Seeking Alpha

SHANGHAI and SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced li...

8 months ago - GlobeNewsWire

SHANGHAI, Sept. 27, 2020 /PRNewswire/ -- Qiming's portfolio company Zai Lab (SEHK:9688, NASDAQ:ZLAB), an innovative commercial-stage biopharmaceutical company, officially listed on the Main Board of The...

8 months ago - PRNewsWire

SHANGHAI and SAN FRANCISCO, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced th...

8 months ago - GlobeNewsWire

Week In Review: Zai Lab To Raise Up To $845 Million In Hong Kong IPO

8 months ago - Seeking Alpha

SHANGHAI and SAN FRANCISCO, Sept. 19, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced detailed positive results from ...

9 months ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), an innovative commercial stage biopharmaceutical company, today announced the...

9 months ago - GlobeNewsWire

Du leads Shanghai-based pharma company Zai Lab, whose $6 billion market cap has increased threefold since its IPO valuation on Nasdaq in 2017.

9 months ago - Forbes

- ZEJULA is the only PARP inhibitor approved as monotherapy for all-comer patients in the first-line and recurrent maintenance treatment settings regardless of biomarker status

9 months ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that detailed clini...

9 months ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du...

9 months ago - GlobeNewsWire

SHANGHAI and SAN FRANCISCO, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that F. Ty Edmondson has been na...

10 months ago - GlobeNewsWire

Zai Lab's (ZLAB) CEO Samantha Du on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

SHANGHAI and SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that the Center for Drug Evaluat...

10 months ago - GlobeNewsWire

-- Company to host Conference Call and Webcast on August 13, 2020 at 8:00 a.m. ET -- SHANGHAI and SAN FRANCISCO, July 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commer...

10 months ago - GlobeNewsWire

About ZLAB

Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops, and commercializes therapeutics to treat oncology, autoimmune, and infectious diseases in China. The company offers ZEJULA for the treatment of breast cancer and non-small cell lung cancer (NSCLC); and Optune, a cancer therapy to treat glioblastoma multiforme. It also develops QINLOCK for the treatment of gastrointestinal stromal tumors; Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhib... [Read more...]

Industry
Biotechnology
IPO Date
Sep 20, 2017
Stock Exchange
NASDAQ
Ticker Symbol
ZLAB
Full Company Profile

Financial Performance

In 2020, Zai Lab's revenue was $48.96 million, an increase of 277.04% compared to the previous year's $12.99 million. Losses were -$268.91 million, 37.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Zai Lab stock is "Strong Buy." The 12-month stock price forecast is 193.08, which is an increase of 22.75% from the latest price.

Price Target
$193.08
(22.75% upside)
Analyst Consensus: Strong Buy